Zarnestra
(Tipifarnib)Phase 3Small molecule
Tipifarnib is used to treat certain types of blood cancers, particularly acute myeloid leukemia (AML) in older adults who cannot tolerate standard chemotherapy. It works by blocking proteins that help cancer cells grow and divide.[1] Zarnestra is currently being investigated across 53 indications[3], with its most advanced program in Phase 3.[1]
Zarnestra is one of 992 small molecule programs targeting Glioma. It is currently in Phase 3.
53
Indications
73
Total Trials
3
Active Trials
991
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 53 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zarnestra
KKura Oncology, Inc.
Phase 3
Tecentriq
RochePreclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Adenocard
AstellasPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Spravato
WWim Janssens
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia9 trials
Show 6 more trials
Breast Cancer8 trials
Show 5 more trials
Glioblastoma Multiforme5 trials
Myelodysplastic Syndromes4 trials
Non-Small Cell Lung Cancer4 trials
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Completed·—·Phase 1·NCT00025480·12 enrolled
30 more indications
Pancreatic Cancer3 trials
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
Completed·—·Phase 1·NCT00077519·18 enrolled
Patients With Advanced Solid Tumors3 trials
Bladder Cancer2 trials
Chronic Myelogenous Leukemia2 trials
Chronic Myelomonocytic Leukemia2 trials
Lymphoma2 trials
Advanced Cancer2 trials
Melanoma2 trials
Head and Neck Cancer2 trials
Tic Disorder2 trials
Leukemia2 trials
Neutropenia1 trial
Malignant Glioma1 trial
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00005859·136 enrolled
Head and Neck Squamous Cell Carcinoma1 trial
Multiple Myeloma1 trial
Advanced Solid Malignancies1 trial
Metastatic Cancer1 trial
Metastatic Prostate Cancer1 trial
Urothelial Carcinoma1 trial
Neurofibromatosis Type 11 trial
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tipifarnib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Protein Farnesyltransferase Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKura Oncology, Inc.